Atopic Dermatitis Market
Atopic Dermatitis Market Study by Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Biologic Therapies, PDE-4 Inhibitors, Antibiotics, Antihistamines, and Emollients from 2024 to 2034
Analysis of Atopic Dermatitis Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Atopic Dermatitis Market Outlook (2024 to 2034)
According to a report by the International Eczema Council, around 223 million individuals across the globe were experiencing atopic dermatitis in 2022. With the global atopic dermatitis market placed at US$ 12.73 billion in 2024, companies can expect market expansion at a CAGR of 4.3% and a valuation of US$ 19.49 billion by the end of 2034.
Atopic dermatitis widely known as eczema is a skin disorder that causes irritation, redness, and inflammation to the skin. Rising prevalence of eczema is contributing to the market growth. Increasing awareness of skin disorders, a high need for quick detection, and rising popularity of biological drugs are all driving the business ahead.
Global atopic dermatitis market growth is expected to be driven by the emergence of the latest technologies in the medical sector and the introduction of innovative procedures. The rising use of harsh soaps, shampoos, and hand wash are leading to the development of skin conditions such as eczema. This aspect is driving key market players to produce innovative atopic dermatitis solutions such as moisturizers and ointments with escalating healing properties.
- Increasing cases of hand atopic dermatitis are expected to push the North American atopic dermatitis market size to US$ 6.44 billion by 2034.
- Western Europe is estimated to hold 21.7% of the global atopic dermatitis market share in 2024.
| Report Attributes | Details |
|---|---|
| Atopic Dermatitis Market Size (2024E) | US$ 12.73 Billion |
| Forecasted Market Value (2034F) | US$ 19.49 Billion |
| Global Market Growth Rate (2024 to 2034) | 4.3% CAGR |
| South Korea Market Value (2034F) | US$ 837.2 Million |
| Sales of Corticosteroids (2034F) | US$ 4.72 Billion |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How is the Market for Atopic Dermatitis Solutions Evolving?
“Rising Prevalence of Skin Disorders Increasing Need for Modern Dermatological Products”
Dermatological disorders are highly prevalent in various forms across the globe.
- According to the World Health Organization 2023 report, around 1.8 billion people across the globe are living with skin disorders. Viral, bacterial, fungal or parasitic origin, are the most prevalent cause of skin diseases.
Increasing incidence of skin disorders are expected to generate lucrative opportunities for atopic dermatitis solution manufacturers during the coming decade. Other factors, such as the development of novel pipeline drugs and rising demand for subcutaneous biologics and product approvals, are also expected to increase the growth of the atopic dermatitis market throughout the forecast period.
“Technological Advancements Leading to Development of Novel Drugs”
Increasing sales of atopic dermatitis drugs are driven by the emergence of the latest technologies in the healthcare sector and the introduction of innovative procedures.
Rising acceptance and quick expansion of the novel treatment in the emerging economies are expected to boost the demand for skincare ingredients throughout the forecast period. Leading companies are concentrating their efforts on the unveiling of new novel formulations by investing heavily in research and development activities.
- For instance, in January 2022, USFDA approved AbbVie's Rinvoq and Pfizer's Cibinqo to treat moderate-to-severe atopic dermatitis, or eczema, in patients unable to respond to the previous treatments.
What’s Hampering Adoption of Atopic Dermatitis Drugs to Some Extent?
“Lack of Awareness and High Treatment Costs”
Some of the factors hampering the adoption of atopic dermatitis drugs in the underdeveloped countries is due to the lack of awareness, cultural taboo towards skin disorders, high treatment cost, and absence of reimbursement policies. The treatment cost of atopic dermatitis treatment is still a deterrent to its adoption among low-income individuals. Furthermore, stringent regulations for product approvals in some regions are also limiting atopic dermatitis drug sales.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Startup Ecosystem
Arcutis Biotherapeutics is a start-up established in the year 2016 with 50+ FDA products. The company focuses on efficacy, safety, and tolerability for disease management and drug optimization. Its commitment towards innovations is leading to the development of novel drugs for the treatment of immune-mediated skin diseases, including seborrheic dermatitis, atopic dermatitis, plaque psoriasis, and scalp psoriasis.
- In November, 2022 - Arcutis Biotherapeutics, Inc. announced positive excellent outcome from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, in adults and children six years and older with mild to moderate atopic dermatitis (AD).
Country-wise Analysis
What is the Sales Outlook for Atopic Dermatitis Drugs in the United States?
“High Cases of Eczema Leading to Production of Advanced Drugs”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 3.9 Billion |
| Growth Rate (2024 to 2034) | 3.6% CAGR |
| Projected Value (2034F) | US$ 5.58 Billion |
The United States market is anticipated to maintain its supremacy in North America throughout the forecast period. This can be attributed to the presence of early adopters of advanced products, adequate reimbursement coverage for pharmaceutical companies, and presence of key market players. Also, growing cases of skin diseases across all age groups in the United States are poised to create profitable opportunities for atopic dermatitis drug manufacturers.
- According to National Eczema Association, around 31.6 million Americans are living with some form of eczema.
- The U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for EUCRISA® (crisaborole) ointment, 2%, extending the lower age limit from 1 year to 3 months in children with mild-to-moderate atopic dermatitis. EUCRISA was previously allowed for use in adults and children over 2 years of age.
Which European Country Will Be a Lucrative Market for Atopic Dermatitis Solution Providers?
“Presence of Advanced Healthcare Infrastructure and Skilled Dermatologists in Germany”
Increasing awareness about atopic dermatitis, favorable medical reimbursement policies, and presence of well-established healthcare facilities are projected to boost the market size in Germany during the coming decade.
Technological innovations, high R&D investments, and the presence of top dermatologists are further boosting the sales of atopic dermatitis drugs in Germany.
Why is India an Emerging Market for Atopic Dermatitis Drug Producers?
“Favorable Regulatory Policies Attracting Leading Market Players”
| Attribute | India |
|---|---|
| Market Value (2024E) | US$ 711.3 Million |
| Growth Rate (2024 to 2034) | 7.7% CAGR |
| Projected Value (2034F) | US$ 1.49 Billion |
India is a big market for atopic dermatitis drug producers. The presence of favorable regulatory policies, high investments in healthcare expenditure, and rising cases of eczema are attracting atopic dermatitis drug manufacturers to establish their plants in India. Several key market players are collaborating to earn high profits in India, a high-potential economy.
- In January 2024, Glenmark and Pfizer revealed the introduction of Abrocitinib an atopic dermatitis drug in India.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Which is the Prime Distribution Channel for Atopic Dermatitis Drugs?
“Affordability and Easy Availability Boosting Atopic Dermatitis Drug Sales through Retail Pharmacies”
| Attribute | Retail Pharmacies |
|---|---|
| Segment Value (2024E) | US$ 3.76 Billion |
| Growth Rate (2024 to 2034) | 7.4% CAGR |
| Projected Value (2034F) | US$ 7.66 Billion |
According to Fact.MR, a market research and competitive intelligence provider, retail pharmacies are projected to account for 39.3% of the global market share by 2034. Retail pharmacies are expected to be the most profitable distribution channels for atopic dermatitis solutions. This can be attributed to the increasing number of retail pharmacy stores around the world and availability of small molecule drugs.
Furthermore, easy availability of therapeutic drugs at the desired location, affordability, and convenience are some other factors leading retail pharmacies to be the topmost distribution channel for atopic dermatitis solutions.
Why are Topical Atopic Dermatitis Solutions Most Widely Demanded?
“Ease of Use and Quick Results from Topical Atopic Dermatitis Solutions”
| Attribute | Topical |
|---|---|
| Segment Value (2024E) | US$ 5.78 Billion |
| Growth Rate (2024 to 2034) | 5.6% CAGR |
| Projected Value (2034F) | US$ 9.99 Billion |
Topical atopic dermatitis creams or serums are widely preferred due to their easy implantation and quick results. Direct contact of medicine to affected area aids in escalating the healing procedures and quick relief. Several skin disorders including eczema cause high irritation and inflammation near affected area. Manufacturers are focusing on the production of advanced topical atopic dermatitis drugs with escalating and prolong relief properties.
Competitive Landscape
Some of the key players in the atopic dermatitis market include AbbVie Inc., Galderma Laboratories LP, Mylan M.V., Sanofi, Novartis AG., Eli Lilly and Company (Dermira), Incyte Corporation, and Pfizer Inc.
Leading companies are investing heavily in research and development activities to develop innovative atopic dermatitis solutions. The growing demand for natural and plant-based medicinal products is one of the notable atopic dermatitis market trends. Key market players are leveraging on such trends to earn high profits. They are focused on the production of natural and organic skincare products.
- In January 2022, the United States Food and Drug Administration gave approval to Dupixent (dupilumab) for the use of children above 6 months to 5 years.
Key Segments of Atopic Dermatitis Market Research
-
By Product :
- Corticosteroids
- Calcineurin Inhibitors
- Immunosuppressants
- Biologic Therapies
- PDE-4 Inhibitors
- Antibiotics
- Antihistamines
- Emollients
-
By Mode of Administration :
- Topical
- Oral
- Injectable
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Dermatology Clinics
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
- FAQs -
How big is the atopic dermatitis market in 2024?
The global atopic dermatitis market is evaluated at US$ 12.73 billion in 2024.
What is the anticipated value of the atopic dermatitis market for 2034?
The market for atopic dermatitis is forecasted to reach US$ 19.49 billion by 2034.
What is the estimated CAGR for the atopic dermatitis market?
Demand for atopic dermatitis solutions is projected to rise at a CAGR of 4.3% from 2024 to 2034.
What is the current value of the South Korean market?
The market in South Korea is calculated at US$ 463.5 million in 2024.
Which product type is most widely used?
Demand for calcineurin inhibitors is foreseen to rise at a CAGR of 5.2% through 2034.
Who are the key producers of atopic dermatitis treatment solutions?
Some of the leading companies include Pfizer Inc., Teva Pharmaceutical Industries Ltd, Sanofi, and Novartis AG.
Atopic Dermatitis Market
*Mail attachment includes 77 figures & 18 tables